OKYO Pharma shares are trading higher after the company announced it secured a US Patent covering OK-101s potential to treat symptoms of dry eye disease.
Portfolio Pulse from Benzinga Newsdesk
OKYO Pharma's shares rose following the announcement of a US Patent for OK-101, a treatment for dry eye disease.
August 27, 2024 | 7:20 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
OKYO Pharma's stock price increased after the company announced it received a US Patent for OK-101, which is aimed at treating dry eye disease.
The announcement of a US Patent for OK-101 is a significant milestone for OKYO Pharma, as it strengthens the company's intellectual property and potential market position in treating dry eye disease. This positive development is likely to boost investor confidence, leading to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100